VLDLR / VLDL Receptor Antibody

VLDLR / VLDL Receptor Antibody Datasheet

VLDLR / VLDL Receptor Antibody Product Information

• Immunogen: Recombinant Human VLDLR / VLDL Receptor protein (Catalog#11075-H08H)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 04
• Ig Type: Mouse IgG1
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human VLDLR / VLDL Receptor (rh VLDLR / VLDL Receptor; Catalog#11075-H08H; NP_003374.3; Met 1-Ser 797). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

VLDLR / VLDL Receptor Antibody Usage Guide

• Specificity: Human VLDLR / VLDL Receptor
• No cross-reactivity in ELISA with

  Human cell lysate (293 cell line)

• Direct ELISA: This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human VLDLR. The detection limit for Human VLDLR is approximately 0.039 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

VLDLR / VLDL Receptor Antibody Background

The very low density lipoprotein receptor, known as VLDLR, is a single-pass type 1 integral membrance protein and a member of the LDL receptor family. This receptor family includes LDL receptor, LRP, megalin, VLDLR and ApoER2, and is characterized by a cluster of cysteine-rich class A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats and an O-linked sugar domain. VLDLR contains 3 EGF-like domains, 8 LDL-receptor class A domains, as well as 6 LDL-receptor class B repeats, and is abundant in heart, skeletal muscle, also ovary and kidney, but not in liver. VLDLR binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. VLDLR mediates the phosphorylation of mDab1 (mammalian disabled protein) via binding to Reelin, and induces the modulation of Tau phosphorylation. This pathway regulates the migration of neurons along the radial glial fiber network during brain development. Defects of VLDLR may be the cause of VLDLR-associated cerebellar hypoplasia (VLDLRCH), a syndrome characterized by moderate-to-profound mental retardation, delayed ambulation, and predominantly truncal ataxia.

References

1. Trommsdorff, M. et al., 1999. Cell. 97: 689-701.
2. Mikhailenko, I. et al., 1999. J. Cell Sci. 112: 3269-3281.
3. Sato, A. et al., 1999. Biochem. J. 341: 377-383.
4. Hiesberger, T. et al., 1999. Neuron 24: 481-489.
5. Tiebel, O. et al., 1999. Atherosclerosis 145: 239-251.
6. Boycott, K.M. et al., 2005,Am. J. Hum. Genet.77 (3): 477-483.
7. Moheb, L.A. et al., 2008, Eur. J. Hum. Genet.16 (2): 270-273.